The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

This settlement resolves allegations that between March 1, 2020, and September 30, 2022, Biohaven paid kickbacks to providers to present at speaker programs designed to promote Nurtec to Medicaid ...

Other products such as Eliquis, Nurtec, Vyndaqel and Ibrance helped drive the sales beat as well. On the flip side, vaccines Prevnar and Abrysvo underperformed expectations. Pfizer expects $1B hit ...

Nurtec ODT/Vydura globally, up 39% operationally, driven primarily by strong demand in the U.S. and, to a much lesser extent, recent launches in international markets, partially offset by lower ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

but one of the conclusions of the pilot was that a pre-requisite for adoption will be "robust systems in place ensuring that the patient can easily access the package leaflet for their medicine in ...

Pharma giant Pfizer has agreed to pay $59 million to settle a federal lawsuit accusing a local biopharmaceutical company of paying “kickbacks” to healthcare providers to induce them to prescribe its ...

Pfizer has agreed to pay $59,746,277, plus interest, on behalf of Biohaven to resolve allegations that Biohaven engaged in unlawful kickback practices to encourage providers to prescribe Nurtec ...